342 related articles for article (PubMed ID: 33387196)
1. Anthracycline-induced cytotoxicity in the GL261 glioma model system.
Tavener AM; Phelps MC; Daniels RL
Mol Biol Rep; 2021 Jan; 48(1):1017-1023. PubMed ID: 33387196
[TBL] [Abstract][Full Text] [Related]
2. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
3. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.
Siegsmund MJ; Stendler A; Kreukler C; Köhrmann KU; Alken P
Eur Urol; 1997; 31(3):365-70. PubMed ID: 9129933
[TBL] [Abstract][Full Text] [Related]
4. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
6. Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin.
Cairo MS; Toy C; Sender L; van de Ven C
J Leukoc Biol; 1990 Mar; 47(3):224-33. PubMed ID: 2155275
[TBL] [Abstract][Full Text] [Related]
7. The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.
Forrest RA; Swift LP; Evison BJ; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Chemother Pharmacol; 2013 Mar; 71(3):809-16. PubMed ID: 23263186
[TBL] [Abstract][Full Text] [Related]
8. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
9. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Hargrave RM; Davey MW; Davey RA; Kidman AD
Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
[TBL] [Abstract][Full Text] [Related]
10. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.
Schott B; Robert J
Biochem Pharmacol; 1989 Nov; 38(22):4069-74. PubMed ID: 2597184
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of demethoxydaunorubicin with other anthracyclines on generation of oxygen radicals and clonogenic survival of fibroblasts.
Grankvist K; Stendahl U; Henriksson R
Pharmacol Toxicol; 1989 Jul; 65(1):40-4. PubMed ID: 2780507
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Roberts NB; Alqazzaz A; Hwang JR; Qi X; Keegan AD; Kim AJ; Winkles JA; Woodworth GF
J Neurooncol; 2018 Dec; 140(3):497-507. PubMed ID: 30132163
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Targeted Controlled Delivery of Chemotherapeutic Anthracycline Derivatives Using Apoferritin Nanocage Carriers.
Kurzątkowska K; Pazos MA; Herschkowitz JI; Hepel M
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572999
[TBL] [Abstract][Full Text] [Related]
16. Pro-apoptotic activity of new analog of anthracyclines--WP 631 in advanced ovarian cancer cell line.
Gajek A; Denel M; Bukowska B; Rogalska A; Marczak A
Toxicol In Vitro; 2014 Mar; 28(2):273-81. PubMed ID: 24287111
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
Kaklamani VG; Gradishar WJ
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
[TBL] [Abstract][Full Text] [Related]
19. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A
JCI Insight; 2019 Feb; 5(6):. PubMed ID: 30830863
[TBL] [Abstract][Full Text] [Related]
20. Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Коbylinska LI; Klyuchivska OY; Grytsyna II; Finiuk N; Panchuk RR; Starykovych MO; Lehka L; Lesyk RB; Zіmenkovsky BS; Stoika RS
Croat Med J; 2017 Apr; 58(2):150-159. PubMed ID: 28409498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
